Document:

Amendment No.5 to Product Development and Commercialization Agreement

 Exhibit 10.17 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
 AMENDMENT NO. 5 
 to 
 PRODUCT DEVELOPMENT AND 

COMMERCIALIZATION AGREEMENT 
 This Amendment No. 5 (“Amendment No. 5”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT entered into and made effective as of the 22nd day of August, 2006, and as amended by Amendment No. 1
effective as of the 30th day of September, 2007, by
Amendment No. 2 effective as of the 6th day of
October 2008, by Amendment No. 3 effective as of the 22nd day of August 2009, and by Amendment No. 4 effective as of the
26th day of February, 2010 (the
“Agreement”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company
existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”,
is hereby entered into by the Parties with an Amendment No. 5 effective date of November 15, 2010 (the “Amendment No. 5 Effective Date”). 

WHEREAS, the Parties now agree to progress the Development Candidate CCX168 targeting the Collaboration Target C5aR in a non-Major
Indication, and that development activities in such non-Major Indication shall satisfy certain obligations under the Agreement with respect to Major Indications; and 
 WHEREAS, the Parties now agree, as a result, to amend certain milestone payments with respect to the progression of Development Candidate CCX168 in a non-Major Indication, as set forth in this
Amendment No. 5, and to establish or clarify certain other issues with respect to the Agreement. 
 NOW THEREFORE,
in consideration of the foregoing premises and the mutual covenants set forth below, the Parties do hereby amend the Agreement and otherwise agree as follows: 
 1.        No Additional Changes; Use of Capitalized Terms.    Except as amended hereby, all other provisions of the Agreement will
remain unchanged and remain in full force and effect and the Agreement, as amended, is hereby ratified, confirmed and reaffirmed in all respects. The Agreement together with this Amendment No. 5 will be read, taken and construed as one and the
same instrument. All terms used in this Amendment No. 5, but not defined herein, will have the same meaning set forth for that term in the Agreement. 
 2.        Proof of Concept Trial.    The Parties agree that pursuant to Section 3.6.3 of the Agreement, they have selected
renal vasculitis, a non-Major Indication, as an Indication to 

  
 1 

 
pursue for the Development Candidate CCX168. Notwithstanding anything in the Agreement to the contrary, the Parties agree that the first Phase 2 Clinical Trial of CCX168 that is reasonably
designed to satisfy the PoC Criteria in a non-Major Indication (e.g., an orphan indication such as renal vasculitis) approved by the Parties shall be deemed a Proof of Concept Trial (or PoC Trial) for all purposes under the Agreement,
notwithstanding that such Indication is not a Major Indication. Without limiting the generality of the foregoing: 
 (a)        completion of such Phase 2 Clinical Trial by ChemoCentryx shall satisfy ChemoCentryx’s obligation under Section 3.7.1 to undertake Development
of CCX168 through completion of a PoC Trial; and 
 (b)        if based
on such Phase 2 Clinical Trial, the JSC determines in accordance with Section 3.8.2 that CCX168 satisfies the applicable PoC Criteria, CCX168 shall be deemed an Option Compound, and GSK’s Product Option under Section 4.1 of the
Agreement shall apply to such Option Compound (and its Back-up Compounds CCX1378 and CCX1641, which were designated by the JSC on March 19, 2009, and accepted by GSK in the context of the[***]), such Option Compound and its designated Back-up
Compounds collectively referred to as one set of Progressed Compounds, all of which are included within and subject to a single Product Option exercise. GSK would owe to ChemoCentryx the Non-CCR9 Option Exercise Fee under Section 6.3.2 of the
Agreement for exercise of such Product Option. 
 3.        Amendment of
Section 6.4.2, Footnote 3. Section 6.4.2, Footnote 3 shall be amended to add the following sentence to the end of Footnote 3: 
 “[***]” 
 3.        This
Amendment No. 5 may be executed in counterparts and all such counterparts taken together shall be deemed to constitute one and the same instrument. 
 4.        This Amendment No. 5 and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with
the laws of the State of Delaware, U.S.A., without reference to conflicts of laws principles. 

***    Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  
 2 

 IN WITNESS WHEREOF, each of the Parties has caused this Amendment No. 5 to be
duly executed by its duly authorized representative as of the Amendment No. 5 Effective Date. 
  

			
	GLAXO GROUP LIMITED
		
	 By:
	 	
/s/ Paul Williamson                   
                                     

		
	 Name:
	 	 Paul Williamson                

		
	 Title:
	 	Authorised Signatory
for and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate
Director                                        
    
	
	 CHEMOCENTRYX, INC.

		
	 By:
	 	 /s/ Thomas J.
Schall                            

		
	 Name:
	 	 Thomas J.
Schall                                

		
	 Title:
	 	 President and Chief Executive Officer

  
 3Amendment to Series D Preferred Stock Subscription Agreement

 Exhibit 10.19 

 
 AMENDMENT TO SERIES D PREFERRED STOCK SUBSCRIPTION AGREEMENT

 This Amendment (the “Amendment”) to Series D Preferred Stock Subscription Agreement (the
“Agreement”) dated as of November 8, 2007 is entered into by and between ChemoCentryx, Inc., a Delaware corporation (the “Company”) and Glaxo Group Limited, a limited liability company organized
under the laws of England doing business as GlaxoSmithKline (“GSK”). 
 The Company and GSK wish to
amend Sections 7.18 and 7.19 of the Agreement which relate only to the rights and obligations of the Company and GSK to provide for the purchase by GSK of $7 million of the Company’s Common Stock concurrently with an initial public offering of
the Company’s Common Stock. The remainder of the Agreement shall remain in full force and effect. 
 Section 7.8 of
the Agreement permits the amendment of such provisions with only the consent of GSK and the Company. 
 Capitalized terms used
herein without definition shall have the same meanings as in the Agreement. 
 Accordingly, the Company and GSK each hereby
agree that Sections 7.18 and 7.19 are hereby amended and restated to read in their entirety as follows: 

7.18  Purchase of Common Stock in Initial Public Offering; Selling Restrictions. 

(a)      GSK agrees to purchase an aggregate amount of $7 million of the Company’s Common Stock (the
“Common Shares”) at a per share price equal to the per share initial public offering price in a private placement closing (the “Common Closing”) to be held concurrently with the closing of an initial public offering
of at least $25 million in gross proceeds to the Company. At the Common Closing the Company shall deliver to GSK one or more Common Stock certificates, in accordance with GSK’s reasonable request. Each such certificate shall be registered in
the name of GSK or one of its affiliates as GSK shall instruct. The Company’s obligation to issue and deliver such shares at the Common Closing shall be subject to the following conditions, any of which may be waived by the Company:
(i) receipt by the Company of a certified or official bank check or checks or wire transfer of funds in the full amount of the purchase price for the Common Shares; (ii) the accuracy in all material respects of the representations of GSK
made herein as of the Common Closing; (iii) no judgment, decree, injunction, order or ruling of any court or governmental or regulatory body would be violated by the consummation of the transaction; and (iv) all authorizations, approvals,
or permits, if any, of any governmental authority or regulatory body which are legally required shall have been obtained and be effective. GSK’s obligations to purchase the Common Shares at the Common Closing shall be subject to the following
conditions, any of which may be waived by GSK: (i) receipt by GSK of one or more certificates representing the Common Shares; and (ii) the accuracy in all material respects of the representations and warranties of the Company made herein
as of the Common Closing, provided, however, that for this purpose the representations and warranties of the Company included herein shall be deemed to be updated and modified by information included in the final prospectus relating to the
Company’s initial public offering, a copy of which 

 
shall have been furnished to GSK and on which GSK shall be entitled to rely. GSK acknowledges that the Common Shares will not be registered and will be appropriately legended as restricted stock.
It is the intent of the Company and GSK that the Common Shares purchased hereunder be treated as “Registrable Securities” pursuant to the Investors Rights Agreement. The Company shall use its reasonable best efforts to obtain any necessary
consents from the necessary parties to the Investors Rights Agreement to effect such an amendment to the Investors Rights Agreement prior to the closing of the initial public offering. 

(b)      GSK agrees that for a period commencing on the date of the Closing and ending on the earliest of
(a) the third anniversary of the date of the Closing, (b) the consummation of a Qualified IPO (as defined in the Investors Rights Agreement) and (c) the closing of a transaction in which a third party acquires a majority of the
outstanding voting shares of the Company (the “Restricted Period”), neither GSK, nor any of its affiliates, shall offer, sell, contract to sell, pledge, grant an option to purchase, make a short sale or otherwise dispose of
any Securities held by GSK or any of its affiliates, or grant an option or other rights to any person or entity to acquire any Securities, without the prior written consent of the Company; provided that notwithstanding anything in this
Section 7.18 to the contrary, GSK and its affiliates shall be bound by the Market-Standoff Agreement in Section 1.14 of the Investors Rights Agreement. During the Restricted Period, the consent of the Company shall not be required for the
transfers by GSK of all or a portion of the Securities to its affiliates (a “Permitted Transferee”); provided, however, that such affiliate agrees to become a party to, and be bound by, all of the terms and conditions of this
Agreement by duly executing and delivering a joinder agreement. During the two year period from and after the expiration of the Restricted Period, GSK and/or its affiliates shall not offer, sell, contract to sell, pledge, grant an option to
purchase, make a short sale or otherwise dispose of any of the Securities purchased by GSK pursuant to this Agreement other than pursuant to a registration statement under the Securities Act or pursuant to Rule 144 under the Securities Act without
the prior written consent of the Company. 
 7.19  Standstill. 

(a)      During the Research Term (as defined in the Product Development and Commercialization Agreement
between the Company and Glaxo Group Limited dated as of August 22, 2006) and the first year thereafter, neither GSK nor any of its affiliates shall, in any manner, directly or indirectly, except as agreed by the Company in writing or as
provided expressly in Sections 7.19(b) or 7.19(c) or otherwise under this Agreement: (i) make, effect, initiate, cause or participate in any acquisition of beneficial ownership of any securities or any assets of the Company; (ii) form,
join or participate in a “group” (as defined in the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) with respect to the beneficial ownership of any securities of the Company; (iii) agree or
offer to take, or encourage or propose (publicly or otherwise) the taking of any action referred to in subsections (i) or (ii) of this Section 7.19(a); or (iv) assist, induce or encourage any other person or entity to take any
action of the type referred to in subsections (i), (ii) or (iii) of this Section 7.19(a). 

(b)      Nothing herein shall prevent GSK or its affiliates (or in the case of Section 7.19(b)(v),
their employees) from: (i) purchasing the Shares at the Closing; (ii) purchasing the Common Shares at the Common Closing, (iii) purchasing additional Securities pursuant to the provisions of the Investors Rights Agreement or the
Certificate; (iv) acquiring Securities issued in 

 
connection with stock splits or recapitalizations; (v) following the consummation of a Qualified IPO (as defined in the Investors Rights Agreement) purchasing Securities for (A) a
pension plan established for the benefit of GSK’s employees, (B) any employee benefit plan of GSK, (C) any stock portfolios not controlled by GSK or any of its affiliates that invest in the Company among other companies, or
(D) any account of a GSK director, officer or employee in such individual’s personal capacity; or (vi) acquiring securities of another biotechnology or pharmaceutical company that beneficially owns any Securities; provided that any
Securities so acquired shall be subject to the provisions of Section 7.18 of this Agreement on the same basis as the Shares purchased pursuant to this Agreement. 
 (c)      GSK and its affiliates shall be free from the restrictions and limitations contained in this Section 7.19 in the event that: (i) the Board of Directors of
the Company publicly announces or publicly acknowledges that (A) the Board of Directors of Company has decided to sell the Company or (B) the Company is for sale; (ii) the Company enters into a written agreement with a third party
providing for a transaction which would give rise to a change of control in the Company; (iii) any third party commences or otherwise undertakes any tender or exchange offer (as such terms are defined or used under the Exchange Act) for the
Company; or (iv) any third party initiates a “solicitation” of “proxies” (as such terms are defined or used in Regulation 14A of the Exchange Act) with respect to the Company. 

The foregoing Amendment is hereby entered into by the Company and GSK as of November 8, 2007. 

 

			
	CHEMOCENTRYX, INC.
		
	By:	 	             /s/ Thomas J.
Schall

		 	Name:  Thomas J. Schall
		 	
Title:    President & Chief Executive        

             Officer

	
	GLAXO GROUP LIMITED
		
	By:	 	             /s/ V. A.
Whyte

		 	 Name:  V. A. Whyte
		 	 Title:    Assistant Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]